Trial Profile
A Phase 1, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLN0128 (an Oral mTORC 1/2 Inhibitor) as a Single Agent and in Combination With Paclitaxel in Adult Patients With Advanced Nonhematologic Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Mar 2020
Price :
$35
*
At a glance
- Drugs Sapanisertib (Primary) ; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Takeda Oncology
- 24 Aug 2018 Status changed from active, no longer recruiting to completed.
- 11 May 2018 Planned End Date changed from 30 Apr 2018 to 31 Jul 2018.
- 30 Jan 2018 Planned end date changed from 31 Oct 2017 to 30 Apr 2018.